A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-10-01

Target enrollment:

Participant gender:

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

PHASE3

EyePoint Pharmaceuticals, Inc.

aflibercept